Anavex announces Phase 2 study of ANAVEX3-71 met its primary endpoint

Anavex (AVXL) Life Sciences announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication. The study successfully achieved its primary endpoint, demonstrating that ANAVEX3-71 was safe and well-tolerated. The safety profile was consistent with previous studies of ANAVEX3-71 in healthy volunteers, with no serious treatment-emergent adverse events and no severe TEAEs reported in either Part A or Part B of the study.